Development of nomogram to predict in-hospital death for patients with intracerebral hemorrhage: A retrospective cohort study

Linwang Hu¹, Jie Yu¹, Jian Deng¹, Hong Zhou¹, Feng Yang² and Xiaohang Lu³*

¹Department of Neurosurgery, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China, ²Department of Pharmacy, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China, ³Department of Critical Care Medicine, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia, China

Aim: This study aimed to investigate the association between systemic immune-inflammation (SII) and the risk of in-hospital death for patients with intracerebral hemorrhage (ICH) in the intensive care units (ICU) and to further develop a prediction model related to SII in predicting the risk of in-hospital death for patients with ICH.

Methods: In this retrospective cohort study, we included 1,176 patients with ICH from the Medical Information Mart for Intensive Care III (MIMIC-III) database. All patients were randomly assigned to the training group for the construction of the nomogram and the testing group for the validation of the nomogram based on a ratio of 8:2. Predictors were screened by the least absolute shrinkage and selection operator (LASSO) regression analysis. A multivariate Cox regression analysis was used to investigate the association between SII and in-hospital death for patients with ICH in the ICU and develop a model for predicting the in-hospital death risk for ICU patients with ICH. The receiver operator characteristic curve was used to assess the predicting performance of the constructed nomogram.

Results: In the training group, 232 patients with ICH died while 708 survived. LASSO regression showed some predictors, including white blood cell count, glucose, blood urea nitrogen, SII, the Glasgow Coma Scale, age, heart rate, mean artery pressure, red blood cell, bicarbonate, red blood cell distribution width, liver cirrhosis, respiratory failure, renal failure, malignant cancer, vasopressor, and mechanical ventilation. A prediction model integrating these predictors was established. The area under the curve (AUC) of the nomogram was 0.810 in the training group and 0.822 in the testing group, indicating that this nomogram might have a good performance.
Conclusion: Systemic immune-inflammation was associated with an increased in-hospital death risk for patients with ICH in the ICU. A nomogram for in-hospital death risk for patients with ICH in the ICU was developed and validated.

KEYWORDS
systemic immune-inflammation, intracerebral hemorrhage, MIMIC-III database, in-hospital death, nomogram

Introduction

Intracerebral hemorrhage (ICH) is the most severe form of stroke characterized by bleeding into the brain parenchyma, which has a 1-month mortality rate of $\sim 50\%$ and has become one of the leading causes of disability and death worldwide (1, 2). A study from the Big Data Observatory platform for stroke in China reported that the in-hospital death rate of ICH was $\sim 5.1\%$, and the 12-month disability rate was $\sim 29.2\%$ (3). The burden of disease for patients with ICH is huge, especially for those in intensive care units (ICUs). Therefore, an early prediction of death risk in patients with ICH is critical for assessing the severity of the disease and making appropriate treatment decisions.

Perihematomal edema (PHE) could occur within hours after ICH, which may trigger an inflammatory response and lead to a secondary brain injury (4, 5). Previously published studies have shown that inflammatory response played an important role in the development of ICH (6, 7). ICH drives inflammatory responses of microglia and T-cell-mediated in the brain, and these inflammatory responses were related to cytokine release and perihematomal edema, which might cause a poor prognosis after ICH (8). Nowadays, some inflammation parameters have been reported that might be associated with the prognosis of
TABLE 1 The characteristics of included patients in the training group.

| Variables                      | Total (n = 940) | Survival group (n = 708) | Death group (n = 232) | Statistics | P     |
|--------------------------------|----------------|--------------------------|-----------------------|------------|-------|
| Age, years, Mean ± SD          | 67.41 ± 15.28  | 66.72 ± 15.33            | 69.53 ± 14.97         | t = −2.44  | 0.015 |
| Gender, n (%)                  |                |                          |                       | χ² = 0.475 | 0.491 |
| Male                           | 553 (58.83)    | 421 (59.46)              | 132 (56.90)           |            |       |
| Female                         | 387 (41.17)    | 287 (40.54)              | 100 (43.10)           |            |       |
| Ethnicity, n (%)               |                |                          |                       | χ² = 0.693 | 0.707 |
| White                          | 696 (74.04)    | 527 (74.44)              | 169 (72.84)           |            |       |
| Black                          | 70 (7.45)      | 54 (7.63)                | 16 (6.90)             |            |       |
| Other*                         | 174 (18.51)    | 127 (17.94)              | 47 (20.26)            |            |       |
| Insurance, n (%)               |                |                          |                       | χ² = 8.127 | 0.017 |
| Medicare                       | 541 (57.55)    | 391 (55.23)              | 150 (64.66)           |            |       |
| Other*                         | 125 (13.30)    | 94 (13.28)               | 31 (13.36)            |            |       |
| Private                        | 274 (29.15)    | 223 (31.50)              | 51 (21.98)            |            |       |
| LOS, days, M (Q1, Q3)          | 3.15 (1.90, 6.99) | 3.07 (1.88, 7.34)       | 3.44 (2.05, 6.14)     | Z = 0.374  | 0.708 |
| Temperature, °C, Mean ± SD     | 36.71 ± 1.51   | 36.69 ± 1.60             | 36.77 ± 1.22          | t = −0.73  | 0.463 |
| Heart rate, times/min, Mean ± SD| 81.45 ± 17.33  | 80.22 ± 16.14            | 85.20 ± 20.11         | t = −3.43  | <0.001|
| SBP, mmHg, Mean ± SD           | 141.85 ± 25.60 | 142.53 ± 24.51           | 139.79 ± 28.64        | t = 1.31   | 0.191 |
| DBP, mmHg, Mean ± SD           | 71.75 ± 17.52  | 72.57 ± 17.02            | 69.87 ± 18.90         | t = 1.79   | 0.074 |
| MAP, mmHg, Mean ± SD           | 91.65 ± 17.97  | 92.49 ± 17.39            | 89.06 ± 19.46         | t = 2.39   | 0.017 |
| SPO2, %, Mean ± SD             | 97.98 ± 3.83   | 97.79 ± 4.20             | 98.53 ± 2.26          | t = −3.42  | <0.001|
| WBC, K/uL, M (Q1, Q3)          | 10.10 (7.60, 13.25) | 9.80 (7.55, 12.60)     | 11.60 (8.40, 15.50)   | Z = 4.312  | <0.001|
| INR, ratio, M (Q1, Q3)         | 1.10 (1.10, 1.40) | 1.10 (1.10, 1.30)      | 1.20 (1.10, 1.60)     | Z = 2.801  | 0.005 |
| MCV, IL, Mean ± SD             | 89.45 ± 6.48   | 89.11 ± 6.10             | 90.48 ± 7.42          | t = −2.55  | 0.011 |
| Magnesium, mEq/L, Mean ± SD    | 1.94 ± 0.32    | 1.95 ± 0.31              | 1.91 ± 0.36           | t = 1.18   | 0.238 |
| Glucose, mg/dL, M (Q1, Q3)     | 134.00 (109.00, 169.00) | 129.00 (108.00, 163.00) | 150.00 (118.00, 198.00) | Z = 5.190  | <0.001|
| Creatinine, mg/dL, M (Q1, Q3)  | 0.90 (0.80, 1.20) | 0.90 (0.80, 1.10)      | 1.00 (0.80, 1.30)     | Z = 1.574  | 0.115 |
| BUN, mg/dL, M (Q1, Q3)         | 18.00 (13.00, 24.00) | 17.00 (13.00, 23.00)    | 20.00 (15.00, 27.50)  | Z = 4.050  | <0.001|
| Bicarbonate, mEq/L, Mean ± SD  | 24.69 ± 3.76   | 24.86 ± 3.60             | 24.16 ± 4.15          | t = 2.30   | 0.022 |
| Neutrophil, %, Mean ± SD       | 78.09 ± 13.77  | 77.66 ± 13.08            | 79.40 ± 15.66         | t = −1.52  | 0.129 |
| Lymphocytes, %, M (Q1, Q3)     | 12.20 (7.80, 19.20) | 13.25 (8.65, 20.15)     | 10.00 (5.95, 16.20)   | Z = −5.076 | <0.001|
| Hematocrit, %, Mean ± SD       | 37.61 ± 6.07   | 37.96 ± 5.74             | 36.55 ± 6.88          | t = 2.82   | 0.005 |
| Hemoglobin, g/dL, Mean ± SD    | 12.83 ± 2.18   | 12.97 ± 2.06             | 12.39 ± 2.46          | t = 3.25   | 0.001 |
| MCHC, %, Mean ± SD             | 34.08 ± 1.41   | 34.15 ± 1.42             | 33.86 ± 1.38          | t = 2.78   | 0.006 |
| RDW, %, Mean ± SD              | 14.39 ± 1.87   | 14.22 ± 1.75             | 14.92 ± 2.11          | t = −4.53  | <0.001|
| SII, M (Q1, Q3)                | 1520.30 (788.22, 2607.95) | 1499.97 (777.82, 2401.21) | 1869.86 (848.88, 3453.13) | Z = 3.396  | <0.001|
| SAPS II, M (Q1, Q3)            | 34.00 (27.00, 44.00) | 32.50 (26.00, 40.00)    | 43.00 (35.00, 54.00)  | Z = 11.167 | <0.001|
| SOFA, M (Q1, Q3)               | 4.00 (2.00, 6.00) | 3.00 (2.00, 5.50)       | 6.00 (5.00, 8.00)     | Z = 12.533 | <0.001|
| GCS, M (Q1, Q3)                | 14.00 (11.00, 15.00) | 14.00 (12.00, 15.00)    | 15.00 (7.00, 15.00)   | Z = −0.937 | 0.349 |
| Vasopressor, yes, n (%)        | 34 (3.62)      | 5 (0.71)                 | 29 (12.50)            | χ² = 69.719 | <0.001|

(Continued)
TABLE 1 (Continued)

| Variables                        | Total (n = 940) | Survival group (n = 708) | Death group (n = 232) | Statistics | P       |
|----------------------------------|----------------|-------------------------|-----------------------|------------|---------|
| Mechanical ventilation, yes, n (%) | 535 (56.91)    | 337 (47.60)             | 198 (85.34)           | $\chi^2 = 101.527$ | <0.001  |
| COPD, yes, n (%)                 | 69 (7.34)      | 53 (7.49)               | 16 (6.90)             | $\chi^2 = 0.089$  | 0.765   |
| Lung cancer, yes, n (%)          | 25 (2.66)      | 22 (3.11)               | 3 (1.29)              | $\chi^2 = 2.222$  | 0.136   |
| Atrial fibrillation, yes, n (%)  | 235 (25.00)    | 171 (24.15)             | 64 (27.59)            | $\chi^2 = 1.099$  | 0.295   |
| Liver cirrhosis, yes, n (%)      | 25 (2.66)      | 10 (1.41)               | 15 (6.47)             | $\chi^2 = 17.235$ | <0.001  |
| CHF, yes, n (%)                  | 154 (16.38)    | 107 (15.11)             | 47 (20.26)            | $\chi^2 = 3.377$  | 0.066   |
| Heart disease, yes, n (%)        | 39 (4.15)      | 26 (3.67)               | 13 (5.60)             | $\chi^2 = 1.639$  | 0.201   |
| Diabetes, yes, n (%)             | 182 (19.36)    | 139 (19.63)             | 43 (18.53)            | $\chi^2 = 0.135$  | 0.713   |
| Respiratory failure, yes, n (%)  | 222 (23.62)    | 152 (21.47)             | 70 (30.17)            | $\chi^2 = 7.338$  | 0.007   |
| Hyperlipidemia, yes, n (%)       | 273 (29.04)    | 216 (30.51)             | 57 (24.57)            | $\chi^2 = 2.991$  | 0.084   |
| Renal failure, yes, n (%)        | 138 (14.68)    | 92 (12.99)              | 46 (19.83)            | $\chi^2 = 6.514$  | 0.011   |
| Malignant cancer, yes, n (%)     | 189 (20.11)    | 156 (22.03)             | 33 (14.22)            | $\chi^2 = 6.635$  | 0.010   |
| Hypertension, yes, n (%)         | 653 (69.47)    | 492 (69.49)             | 161 (69.40)           | $\chi^2 = 0.001$  | 0.978   |
| Time, days, M (Q1, Q3)           | 23.54 (14.23, 30.38) | 25.15 (18.14, 31.92) | 14.94 (8.80, 23.38) | $Z = 10.024$    | <0.001  |

Other*: Asian, Hispanic, and so on. Other**: Government, Medicaid, and self-pay; LOS, length of stay; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean artery pressure; SpO2, oxygen saturation; SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment; GCS, Glasgow Coma Scale; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; WBC, white blood cell count; RBC, red blood cell; SII, systemic immune-inflammation; INR, international normalized ratio; MCV, mean corpuscular volume; Scr, creatinine; BUN, blood urea nitrogen; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood cell distribution width; $\chi^2$: Chi-square test; Z: Mann–Whitney U rank sum test.

ICH, such as the neutrophil to lymphocyte ratio (NLR), the platelet to lymphocyte ratio (PLR), and the lymphocyte to monocyte ratio (LMR) (9–11). Recently, the systemic immune-inflammation (SII) index, as an integrated indicator based on peripheral lymphocytes, neutrophils, and platelets counts, was considered a new inflammatory marker and could reflect the local immune response and systemic inflammation (12, 13), which has a good prognostic value in a variety of tumors. Huang et al. highlighted that SII was related to the prognosis of patients with cervical cancer, and the nomogram based on SII showed a good predictive value for predicting postoperative survival of patients with cervical cancer (14). Nevertheless, as far as we know, there were few studies to evaluate the relationship between the SII and in-hospital death of patients with ICH in the ICU, and the predictve value of SII on in-hospital death.

Herein, the present study aimed to investigate the association between SII and the risk of in-hospital death for patients with ICH in the ICU and to further combine other prognostic indicators to develop a prediction model in predicting the risk of in-hospital death for patients with ICH.

Methods

Data sources and study population

In this retrospective cohort study, all data were derived from the Medical Information Mart for Intensive Care (MIMIC-III) database. MIMIC-III is a large, freely-available database, containing the de-identified health-related data of patients admitted to the ICU of the Beth Israel Deaconess Medical Center in 2001–2012 (15). This database collects some information, such as demographic characteristics, vital signs, laboratory tests, and imaging examinations (https://mimic.mit.edu/).

Included criteria are as follows: The patients diagnosed with ICH according to International Classification of Diseases 9th revision (ICD-9) codes = 431, 432, 9487, and 77210–77214 from the MIMIC-III database. Excluded criteria are as follows: The patients who (1) aged <18 years; (2) were hospitalized in the ICU for <24 h; (3) had missing data of SII; and (4) had missing data of other covariates. According to these inclusion and exclusion criteria, a total of 1,176 eligible patients with ICH were ultimately included in this retrospective cohort study (Figure 1). Since this study used data from an anonymous public database that was approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center (Boston, MA) and the Massachusetts Institute of Technology (Cambridge, MA), it was not necessary to obtain the approval of an ethics committee from the People's Hospital of Ningxia Hui Autonomous Region.

Screening for potential predictors

In the present study, we extracted data about included patients from the MIMIC-III database (16, 17): age, gender,
The predictors were selected in the LASSO regression analysis by the 10-fold cross-validation, and the optimal penalty parameter was 0.00155. LASSO, least absolute shrinkage and selection operator; MAP, mean artery pressure; SpO₂, oxygen saturation; WBC, white blood cell count; RBC, red blood cell; MCV, mean corpuscular volume; BUN, blood urea nitrogen; RDW, red blood cell distribution width; GCS, Glasgow Coma Scale; and SII, systemic immune-inflammation.

ethnicity, temperature (°C), heart rate (times/min), systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), mean artery pressure (MAP, mmHg), oxygen saturation (SpO₂, %); the sequential organ failure assessment (SOFA) total score, the simplified acute physiology score II (SAPS II), the Glasgow Coma Scale (GCS), vasopressor, mechanical ventilation; comorbidities: chronic obstructive pulmonary disease (COPD), lung cancer, atrial fibrillation, liver cirrhosis, congestive heart failure (CHF), heart disease, diabetes, respiratory failure, hyperlipidemia, renal failure, malignant cancer, and hypertension; laboratory parameters: white blood cell count (WBC, K/µl), red blood cell (RBC, m/µl), sodium (mEq/L), potassium (mEq/L), calcium (mg/dl), magnesium (mg/dl), phosphate (mg/dl), platelet (K/µl), international normalized ratio (INR), mean corpuscular volume (MCV, fl), glucose (mg/dl), creatinine (Scr, mg/dl), blood urea nitrogen (BUN, mg/dl), bicarbonate (mEq/L), neutrophil (%), lymphocyte (%), hematocrit (%), hemoglobin (g/dl), mean corpuscular hemoglobin concentration (MCHC, %), red blood cell distribution width (RDW, %), and SII.

Outcome and follow-up

The primary endpoint of this study was regarded as in-hospital death, and the starting point of follow-up was defined as the date of the patient's admission with a median follow-up time of 23.48 (14.83, 30.25) days. The SII index was calculated by the following formula: platelet × neutrophil/lymphocyte (13).
Renal failure, yes 0.84 (0.55, 1.27) 0.104

TABLE 2 The HR of the selected predictor in multivariate Cox regression analysis.

| Variables         | HR (95%CI) | P     |
|-------------------|------------|-------|
| Age               | 1.54 (1.32, 1.81) | <0.001 |
| MAP               | 0.95 (0.83, 1.09) | 0.440 |
| Heart rate        | 1.16 (1.03, 1.32) | 0.019 |
| GCS               | 0.85 (0.76, 0.95) | 0.004 |
| WBC               | 1.01 (0.94, 1.09) | 0.716 |
| Glucose           | 1.18 (1.07, 1.32) | 0.001 |
| BUN               | 0.99 (0.86, 1.13) | 0.840 |
| SII               | 1.12 (1.02, 1.22) | 0.013 |
| RBC               | 0.96 (0.83, 1.11) | 0.569 |
| Bicarbonate       | 1.09 (0.96, 1.25) | 0.185 |
| RDW               | 1.22 (1.08, 1.38) | 0.001 |
| Vasopressor, yes  | 3.60 (2.22, 5.83) | <0.001 |
| Mechanical ventilation, yes | 3.99 (2.69, 5.91) | <0.001 |
| Liver cirrhosis, yes | 2.36 (1.31, 4.24) | 0.004 |
| Respiratory failure, yes | 0.56 (0.40, 0.76) | <0.001 |
| Renal failure, yes | 0.84 (0.55, 1.27) | 0.409 |
| Malignant cancer, yes | 0.73 (0.50, 1.07) | 0.104 |

HR, hazard ratio; CI, confidence interval; MAP, mean artery pressure; GCS, Glasgow Coma Scale; WBC, white blood cell count; BUN, blood urea nitrogen; SII, systemic immune-inflammation; RBC, red blood cell; RDW, red blood cell distribution width.

Results

Characteristics of patients with ICH

A total of 1,176 patients with ICH were included in this study. These eligible patients with ICH were randomly divided into the training group (n = 940) and the testing group (n = 236). In the training group, 232 patients with ICH died and 708 survived, and the baseline characteristics of patients are listed in Table 1. The patients with ICH in the death group, with a mean age of 69.53 years, were older than the survival group of 66.72 years. We found that the patients with ICH in the survival group were more likely to suffer from respiratory failure, renal failure, and mechanical ventilation than those in the death group. In addition, the patients with ICH in the death group had a higher SII index compared with the survival group.

SII was associated with the risk of in-hospital death in ICU patients with ICH

As shown in Figure 2, 17 predictors were identified through the LASSO regression analysis. These predictors included WBC, glucose, BUN, SII, GCS, age, heart rate, MAP, RBC, bicarbonate, RDW, liver cirrhosis, respiratory failure, renal failure, malignant cancer, vasopressor, and mechanical ventilation. The result of the multivariate Cox regression analysis showed (Table 2) that SII was associated with the risk of in-hospital death among patients
with ICH in the ICU. Notably, SII might be an independent risk factor of in-hospital death for patients with ICH in the ICU, with an HR of 1.12 (95% CI: 1.02–1.22).

Development and validation of prediction nomogram

In the training group, a prediction model integrating WBC, glucose, BUN, SII, GCS, age, heart rate, MAP, RBC, bicarbonate, RDW, liver cirrhosis, respiratory failure, renal failure, malignant cancer, vasopressors, and mechanical ventilation was established. Additionally, for visualizing the prediction model, we plotted a nomogram to predict the probability of in-hospital death for patients with ICH (Figure 3). For example, as shown in Figure 4, the patient was 60 years old with a heart rate of 62 times/min. The MAP was 92 mmHg and the WBC was 15.9 K/µl. The RBC was 4.38 m/µl and the glucose was 111 mg/dl. The BUN was 16 mg/dl and the bicarbonate was 26 mEq/L. The RDW was 13.5% and the GCS was 15. The patient had no complications with liver cirrhosis, respiratory failure, renal failure, or malignant cancer. In addition, the patient did not use vasopressors and mechanical ventilation. According to the nomogram, the total point was 723 and the corresponding predicted probability was 0.042, which indicated a lower risk of death and was in line with the actual outcome of the patient. An online prediction nomogram is available: https://os-model.shinyapps.io/DynNomapp/.

According to the ROC analysis (Figure 5 and Table 3), the area under the curve (AUC) of the nomogram (training group: AUC = 0.810, 95% CI: 0.779–0.840; testing group: AUC = 0.822, 95% CI: 0.765–0.880) was significantly higher than the SOFA (training group: AUC = 0.772, 95% CI: 0.740–0.804; testing group: AUC = 0.745, 95% CI: 0.673–0.818) and SAPS II (training group: AUC = 0.744, 95% CI: 0.708–0.780; testing group: AUC = 0.718, 95% CI: 0.646–0.790) scores. Furthermore, Table 3 also displays that the nomogram has good accuracy, specificity, sensitivity, positive predictive value (PPV), and
An example for the application of the nomogram. BUN, blood urea nitrogen; WBC, white blood cell count; RBC, red blood cell; MAP, mean arterial pressure; SII, systemic immune-inflammation; GCS, Glasgow Coma Scale; and RDW, red blood cell distribution width.

Discussion

In this retrospective cohort study, we found that SII was an independent risk factor of in-hospital death for patients with ICH in the ICU. A prediction model integrating WBC, glucose, BUN, SII, GCS, age, heart rate, MAP, RBC, bicarbonate, RDW, liver cirrhosis, respiratory failure, renal failure, malignant cancer, vasopressors, and mechanical ventilation was established. To our knowledge, this is the first study to explore the relationship between SII and the in-hospital death risk of patients with ICH in the ICU and develop and validate a nomogram associated with SII to predict the risk of in-hospital death among patients with ICH in the ICU. This nomogram showed a good performance to predict the in-hospital death risk for patients with ICH in the ICU in both the training and testing groups.

Inflammatory molecules, as key participants in the secondary injury process after ICH, were also associated with a poor prognosis of ICH (19). For example, an increased C-reactive protein (CRP) level has been found to be a risk factor for predicting an unfavorable prognosis of primary ICH (20). In the study of Miao et al., Interleukin 33 (IL-33) on admission may also be a prognostic indicator of ICH (21). Despite the fact that these inflammatory molecules showed a good performance value in predicting the prognosis of patients with ICH, their clinical application was limited due to the high cost of detection. SII, as an innovative inflammatory biomarker, has been proven to comprehensively reflect the inflammatory state in the body.
The receiver operator characteristic (ROC) curves of the nomogram and other scoring system. AUC, area under the curve; CI, confidence interval; SOFA, sequential organ failure assessment; and SAPS II, simplified acute physiology score II.

Recently, a nomogram has been widely used as a prognostic tool to predict individual probabilities of clinical events by using individual variables (29). For the in-hospital death risk of patients with ICH in the ICU, our study is the first to provide a simple and effective nomogram related to SII. The clinician could calculate the score of each indicator and then add up each score to get the total score, which could correspond to the probability of in-hospital death risk in the nomogram. We believed that the nomogram might help clinicians to quickly and easily understand the risk of death of patients and make timely individualized prevention. Not only that, the nomogram also might show good predicting performance in the in-hospital death risk of patients with ICH in the ICU by the ROC analysis, calibration curve, and DCA. In addition, we compared the predictive ability between the proposed nomogram and the two traditional predictive scoring systems (SOFA and SAPS II). The result also found that the nomogram showed a better predictive ability than the SOFA and SAPS II.

However, the present study had several limitations. First, as a single-center and retrospective study, the sample size was relatively small. Although the nomogram might have a good performance for predicting the death risk of in-hospital patients with ICH in the ICU through internal verification, this nomogram was constructed based on the U.S. population who were hospitalized in the ICU for >24 h, and these patients may be admitted to the ICU as a result of a variety of other factors, such as self-selecting for patients with a worse prognosis. Thus, its generalizability to other populations was still unclear. More prospective and multi-center studies are needed to confirm this result in the future. Second, because all

The SII index is composed of neutrophils, lymphocytes, and platelets in which the three components are indicators of blood routine examination (23). In general, a blood routine is a routine examination for all critically ill hospitalized patients. Therefore, compared with other inflammatory indicators, the SII index is simpler, faster, and more inexpensive for clinical application (23).

In this study, the findings indicated that the SII index might be an independent risk factor for in-hospital death among patients with ICH in the ICU, and the higher the SII level, the higher the risk of in-hospital mortality may be. The mechanisms behind the association of SII and poor prognosis of ICH are still unclear so far, and the explanation might be as follows: an increase in SII levels implies a relative increase of platelet and neutrophil counts or a relative decrease of lymphocytes. Platelets are considered an important component of the hemostatic system (24). When patients suffer from ICH, the platelet count in the peripheral circulation increase, leading to a hypercoagulable state that might increase the risk of adverse outcomes (25, 26). In general, damage to vulnerable parts of the central nervous system may increase the sympathetic system or the hypothalamic-pituitary-adrenal axis, which may favor apoptosis of peripheral lymphocytes and lead to a decrease in the number of lymphocytes, thus contributing to a lower immune capacity and a higher risk of infection (27). Neutrophils can induce neurotoxicity through the release of pro-inflammatory cytokines, free radicals, and other toxic chemicals, which further lead to the destruction of the blood-brain barrier and exacerbate the brain damage caused by ICH (26–28).
TABLE 3 Predictive value of the nomogram.

| Cut off | AUC (95%CI) | Accuracy (95%CI) | Specificity (95%CI) | Sensitivity (95%CI) | PPV (95%CI) | NPV (95%CI) |
|---------|-------------|------------------|---------------------|--------------------|-------------|-------------|
| Nomogram | Training group | 0.701 | 0.810 (0.779–0.840) | 0.695 (0.661–0.729) | 0.650 (0.581–0.719) | 0.450 (0.401–0.500) | 0.899 (0.874–0.925) |
|           | Testing group | 0.712 | 0.695 (0.636–0.754) | 0.695 (0.636–0.754) | 0.650 (0.581–0.719) | 0.450 (0.401–0.500) | 0.899 (0.874–0.925) |
| SOFA     | Training group | 0.522 | 0.872 (0.740–0.880) | 0.669 (0.639–0.699) | 0.631 (0.596–0.667) | 0.784 (0.732–0.837) | 0.411 (0.365–0.457) | 0.899 (0.873–0.926) |
|           | Testing group | 0.745 | 0.673 (0.681–0.818) | 0.712 (0.654–0.770) | 0.749 (0.686–0.811) | 0.585 (0.452–0.718) | 0.403 (0.293–0.512) | 0.962 (0.889–0.979) |
| SAPS II  | Training group | 0.521 | 0.744 (0.708–0.780) | 0.690 (0.661–0.720) | 0.702 (0.668–0.736) | 0.655 (0.594–0.716) | 0.419 (0.368–0.469) | 0.861 (0.833–0.890) |
|           | Testing group | 0.718 | 0.646 (0.670–0.790) | 0.640 (0.579–0.701) | 0.665 (0.587–0.725) | 0.585 (0.452–0.718) | 0.330 (0.235–0.425) | 0.845 (0.786–0.905) |

SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.
Author contributions

LH and XL designed the study. LH wrote the manuscript. JY, JD, HZ, and FY collected, analyzed, and interpreted the data. XL critically reviewed, edited, and approved the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Kirshner H, Schrag M. Management of Intracerebral Hemorrhage: Update and Future Therapies. Curr Neurol Neurosci Rep. (2021) 21:57. doi: 10.1007/s11910-021-01344-9

2. Nawabi J, Knipe H, Elsayed S, Friedrich C, Sporns P, Rusche T, et al. Imaging-Based Outcome Prediction of Acute Intracerebral Hemorrhage. Transl Stroke Res. (2021) 12:958–67. doi: 10.1007/s12975-021-00891-8

3. Tu WJ, Chao BI, Ma L, Yan F, Cao L, Qiu H, et al. (2021). Case-fatality, disability and recurrence rates after first-ever stroke: A study from bigdata observatory platform for stroke of China Brain Res Bull. (2021) 175:130-5028. doi: 10.1016/j.brainsresbull.2021.07.020

4. Li Z, Li M, Shi SX, Yao N, Cheng X, Guo A, et al. Brain transforms natural killer cells that exacerbate brain edema after intracerebral hemorrhage. J Exp Med. (2020) 207:2123. doi: 10.1084/jem.20200213

5. Chen Y, Chen S, Chang J, Wei J, Feng M, Wang R, et al. Perihematoma edema after intracerebral hemorrhage: an update on pathogenesis, risk factors, and therapeutic advances. Front Immunol. (2021) 12:740632. doi: 10.3389/fimmu.2021.740632

6. Bernstein JE, Savla P, Dong F, Zampella B, Wiginton JG, Mulli DE, et al. Inflammatory markers and severity of intracerebral hemorrhage. Cureus. (2018) 10:e3529. doi: 10.7759/cureus.3529

7. Bjerkner Wenneberg S, Odendest Hergöis H, Svedin P, Mallard C, Karlsson T, Adiels M, et al. Association between inflammatory response and outcome after subarachnoid haemorrhage. Acta Neurol Scand. (2021) 143:193-205. doi: 10.1111/ane.13553

8. Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nat Rev Neurol. (2015) 11:524-35. doi: 10.1038/nrneurol.2015.144

9. Qi H, Wang D, Deng X, Peng X. Lymphocyte-to-monocyte ratio is an independent predictor for neurological deterioration and 90-day mortality in spontaneous intracerebral hemorrhage. Med Sci Monit. (2018) 24:9282-91. doi: 10.26592/MSM.916645

10. Zhang W, Shen Y. Platelet-to-lymphocyte ratio as a new predictive index of neurological outcomes in patients with acute intracranial hemorrhage: a retrospective study. Med Sci Monit. (2018) 24:4413–20. doi: 10.12659/MSM.910845

11. Liu S, Liu X, Chen S, Xiao Y, Zhuang W. Neutrophil-lymphocyte ratio predicts the outcome of intracerebral hemorrhage: a meta-analysis. Medicine. (2019) 98:e16211. doi: 10.1097/MD.0000000000016211

12. Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. (2020) 50:e13230. doi: 10.1111/eci.13230

13. Barlt T, Bekos C, Posel M, Alexander R, Poltizerauer S, Stefanie A, et al. The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer. J Gynecol Oncol. (2021) 32:e1. doi: 10.3802/jgo.2021.32.e1

14. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. (2019) 9:32384. doi: 10.1038/s41598-019-39150-0

15. Feng M, McSparron JL, Kien DT, Stone DJ, Roberts DH, Schwartzstein RM, et al. Transthoracic echocardiography and mortality in sepsis: analysis of the MIMIC-III database. Intensive Care Med. (2018) 44:884–92. doi: 10.1007/s00134-018-5208-7

16. Zhou J, Chen H, Liu C, Cai Z, Yang J, Zhang Y, et al. Development and validation of a nomogram to predict the 30-day mortality risk of patients with intracerebral hemorrhage. Front Neurol. (2022) 16:942100. doi: 10.3389/fnins.2022.942100

17. Ji R, Shen H, Pan Y, Wang P, Liu G, Wang Y, et al. A novel risk score to predict 1-year functional outcome after intracerebral hemorrhage and comparison with existing scores. Crit Care. (2013) 17:R275. doi: 10.1186/cc13130

18. Cai XT, Ji LW, Liu SS, Wang MR, Heizati M, Li NF, et al. Derivation and validation of a prediction model for predicting the 5-year incidence of type 2 diabetes in non-obese adults: a population-based cohort study. Diabetes Metab Syndr. (2021) 14:2887–101. doi: 10.2147/DMSO.S349949

19. Walsh KB, Zhang X, Zha X, Wohlbele E, Woo D, Lu L, et al. Intracerebral hemorrhage induces inflammatory gene expression in peripheral blood: global transcriptional profiling in intracerebral hemorrhage patients. DNA Cell Biol. (2018) 37:660–9. doi: 10.1089/dna.2018.4550

20. Löppinen P, Qian C, Tetri S, Juvela S, Huhtakangas J, Bode MK, et al. Predictive value of C-reactive protein for the outcome after primary intracerebral hemorrhage. J Neurosurg. (2014) 121:1374–9. doi: 10.3171/2014.4.JNS132678

21. Miao Y, Zhang ZX, Feng X, Sun WM. IL-33 as a novel serum prognostic marker of intracerebral hemorrhage. Oxid Med Cell Longev. (2021) 2021:5597790. doi: 10.1155/2021/5597790

22. Peng Y, Huang W, Shi Z, Chen Y, Ma J. Positive association between systemic immune-inflammatory index and mortality of cardiogenic shock. Clin Chim Acta. (2020) 511:97–103220. doi: 10.1016/j.cca.2020.09.022

23. Tang Y, Zeng X, Feng Y, Chen Q, Liu Z, Luo H, et al. Association of systemic immune-inflammation index with short-term mortality of congestive heart failure: a retrospective cohort study. Front Cardiovasc Med. (2021) 8:753133. doi: 10.3389/fcmv.2021.753133

24. van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. (2019) 16:166–79. doi: 10.1038/s41569-018-0110-0

25. Tao C, Wang J, Hu X, Ma J, Li H, You C, et al. Clinical value of neutrophil to lymphocyte and platelet to lymphocyte ratio after atheroembolic subarachnoid hemorrhage. Neurocrit Care. (2017) 26:393–401. doi: 10.1007/s12028-016-0332-0

26. Li Y, Wen D, Cui W, Chen Y, Zhang F, Yuan M, et al. The prognostic value of the acute phase systemic immune-inflammation

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2022.968623/full#supplementary-material
index in patients with intracerebral hemorrhage. Front Neurol. (2021) 12:628557. doi: 10.3389/fneur.2021.628557

27. Lattanzi S, Cagnetti C, Rinaldi C, Angelocola S, Provinciali L, Silvestrini M, et al. Neutrophil-to-lymphocyte ratio improves outcome prediction of acute intracerebral hemorrhage. J Neurol Sci. (2018) 387:98–102. doi: 10.1016/j.jns.2018.01.038

28. Gong X, Lu Z, Feng X, Yu C, Xue M, Yu L, et al. Elevated neutrophil-to-lymphocyte ratio predicts depression after intracerebral hemorrhage. Neuropsychiatr Dis Treat. (2020) 16:2153–9. doi: 10.2147/NDT.S269210

29. Wu Y, Hu H, Cai J, Chen R, Zuo X, Cheng H, et al. A prediction nomogram for the 3-year risk of incident diabetes among Chinese adults. Sci Rep. (2020) 10:21716. doi: 10.1038/s41598-020-78716-1

30. Hemphill JC III, Bonovich DC, Besmertis I, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. (2001) 32:891–7. doi: 10.1161/01.STR.32.4.891